The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| TGTX | -24.06% | -37.41% | -8.95% | +2,469% |
| S&P | +17.78% | +74.31% | +11.75% | +440% |
TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.
This commercial-stage biotech develops therapies for B-cell malignancies and autoimmune diseases, leveraging a diverse clinical pipeline.
| Q4 2025 | YOY Change | |
|---|---|---|
| Revenue | $192.57M | 78.0% |
| Gross Profit | $154.37M | 66.5% |
| Gross Margin | 80.16% | -5.5% |
| Market Cap | $4.73B | -79.8% |
| Market Cap / Employee | $11.86M | 0.0% |
| Employees | 399 | 18.0% |
| Net Income | $23.04M | -1.3% |
| EBITDA | $50.56M | 68.5% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2025 | YOY Change | |
|---|---|---|
| Net Cash | $79.15M | -56.0% |
| Accounts Receivable | $305.63M | 136.6% |
| Inventory | 125.6 | 13.7% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $252.67M | 0.0% |
| Short Term Debt | $1.04M | -9.8% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 54.50% | 49.3% |
| Return On Invested Capital | -58.98% | 45.4% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $19.59M | 176.4% |
| Operating Free Cash Flow | $19.66M | 176.7% |
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 161.60 | 96.18 | 13.00 | 10.73 | -95.02% |
| Price to Book | 138.17 | 119.95 | 20.65 | 7.62 | -93.75% |
| Price to Sales | 16.61 | 12.88 | 10.93 | 7.71 | -47.42% |
| Price to Tangible Book Value | 138.17 | 119.95 | 20.65 | 7.62 | -93.75% |
| Price to Free Cash Flow TTM | 109.65 | 41.82 | - | ||
| Enterprise Value to EBITDA | 736.97 | 167.68 | 201.79 | 96.17 | -39.44% |
| Free Cash Flow Yield | 0.9% | 2.4% | - | ||
| Return on Equity | 19.7% | 26.6% | 112.0% | 102.8% | 741.27% |
| Total Debt | $253.71M | $253.72M | $253.72M | $253.71M | -0.00% |
No podcast episodes available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
